US20210046258A1 - Method and apparatus for producing fine concentrated aerosol - Google Patents

Method and apparatus for producing fine concentrated aerosol Download PDF

Info

Publication number
US20210046258A1
US20210046258A1 US17/089,184 US202017089184A US2021046258A1 US 20210046258 A1 US20210046258 A1 US 20210046258A1 US 202017089184 A US202017089184 A US 202017089184A US 2021046258 A1 US2021046258 A1 US 2021046258A1
Authority
US
United States
Prior art keywords
nebulizer
porous medium
aerosol
liquid
pressure drop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/089,184
Inventor
Akper Sadykhov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OMEGA LIFE SCIENCE Ltd
Original Assignee
OMEGA LIFE SCIENCE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2011/000038 external-priority patent/WO2011086552A1/en
Application filed by OMEGA LIFE SCIENCE Ltd filed Critical OMEGA LIFE SCIENCE Ltd
Priority to US17/089,184 priority Critical patent/US20210046258A1/en
Assigned to OMEGA LIFE SCIENCE LTD. reassignment OMEGA LIFE SCIENCE LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SADYKHOV, AKPER
Publication of US20210046258A1 publication Critical patent/US20210046258A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001Particle size control
    • A61M11/003Particle size control by passing the aerosol trough sieves or filters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0021Mouthpieces therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0021Mouthpieces therefor
    • A61M15/0025Mouthpieces therefor with caps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0086Inhalation chambers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/07General characteristics of the apparatus having air pumping means
    • A61M2205/071General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073Syringe, piston type

Definitions

  • partially absorbed refers to a porous medium wherein at least 0.5% of the surface and sub-surface pores contain liquid. In some embodiments, partially absorbed refers to at least 1% liquid contents within the surface and sub-surface pores. In some embodiments, partially absorbed refers to at least 10% liquid contents within the surface and sub-surface pores. In some embodiments, partially absorbed refers to at least 20% liquid contents within the surface and sub-surface pores. In some embodiments, partially absorbed refers to at least 30% liquid contents within the surface and sub-surface pores. In some embodiments, partially absorbed refers to at least 40% liquid contents within the surface and sub-surface pores. In some embodiments, partially absorbed refers to at least 50% liquid contents within the surface and sub-surface pores. In some embodiments, partially absorbed refers to at least 60% liquid contents within the surface and sub-surface pores.
  • the porous medium has a modulus of rigidity of at least 10 GPa (10 9 pascal) at 25° C. In some embodiments, the porous medium has a modulus of rigidity of at least 15 GPa at 25° C. In some embodiments, the porous medium has a modulus of rigidity of at least 20 GPa at 25° C. In some embodiments, the porous medium is substantially devoid of materials having modulus of rigidity lower than 10 GPa at 25° C.
  • a polymer used for forming the porous medium is typically a rigid polymer, such as, a polymer having a Tg (glass transition temperature) in the range of 100 or above 100.
  • the porous medium is in a shape of a disc.
  • Concentrated aerosol refers to the number of droplets per volume unit. Concentrated aerosols include more than 10 8 droplets per cm 3 . Highly concentrated aerosol includes more than 10 9 droplets per cm 3 .
  • FIGS. 2 a -2 b illustrate nebulizer 100 comprising porous medium 102 prior to aerosol production, in a first optional compressed position and a second optional compressed position, respectively;
  • FIG. 2 c illustrates nebulizer 100 comprising porous medium 102 when nebulizer 100 is in aerosol production position, due to the pressure drop generated between upper flat side 102 b and lower flat side 102 a of the porous medium 102 ;
  • FIG. 2 d describes nebulizer 100 comprising porous medium 102 in a position that enables aerosol inhalation.
  • Nebulizer 100 being under a pressure drop across porous medium 102 is illustrated in FIG. 2 c .
  • atomization occurs as a result of the pressure difference across the two sides of porous medium 102 , according to some embodiments.
  • the pressure difference causes the medium to act as a pneumatic multi-nozzle, where the nozzles are defined by pores 2 of porous medium 102 , according to some embodiments.
  • porous medium 102 is configured for multiple uses. According to some embodiments, porous medium 102 is configured for discharge of, and replenishment with, liquid 3 .

Abstract

The present disclosure generally relates to the field of nebulizers for aerosol generation and methods of using same for treating diseases and disorders.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a Continuation of U.S. patent application Ser. No. 15/467,527, filed on Mar. 23, 2017, which is a Continuation-in-Part of U.S. patent application Ser. No. 13/521,718, filed on Jul. 11, 2012 (published as US 20120318259), which is the U.S. National Stage of International Patent Application No. PCT/IL2011/000038, filed on Jan. 12, 2011, which claims the benefit of U.S. Provisional Patent Application No. 61/294,161, filed on Jan. 12, 2010, the contents of each of which are incorporated herein by reference in their entireties.
  • TECHNICAL FIELD
  • The present invention relates to a method and apparatus enabling production of ultra-fine and concentrated aerosol from liquids, for various applications, by using rigid porous material, enabling storage and easy streaming of the aerosol (e.g. for inhalation), fast replacement of liquid carrier device and accuracy of output sprayed dose.
  • BACKGROUND
  • Nebulizers are commonly used for delivering aerosol medication to patients via the respiratory system. Desirably, for efficient delivery of medication, the droplet diameter of the aerosol should be sufficiently small so as to reach the lungs of the patient without being obstructed by objects or organs (such as, the inner surface of the nozzle in the nebulizer and the mouth cavity perimeters) and large enough so as to remain in the lungs during exhalation.
  • The main techniques for producing aerosol in nebulizers include vibrating Mesh technology, jet nebulizers and ultrasonic wave nebulizers. Common to these techniques is the challenge to deliver large volume of medication to the patient while keeping the diameter of the droplets within desired limits.
  • U.S. Pat. No. 2,284,591 discloses a liquid nebulizer device adapted to provide oily compositions specifically to the nose and throat, through preventing their entrance and congestion in the lungs.
  • U.S. Pat. No. 3,812,854 discloses an ultrasonic nebulizer for atomizing a liquid medicament comprising a porous solid body having a defined intercommunicating pore structure where the diameters of at least 75% of the pore openings is in the range of 0.5 to 5 microns.
  • U.S. Pat. No. 4,907,581 discloses a disposable radioactive aerosol inhalation apparatus including a lung aerosol unit, which both generates and traps sub-micron particles, on the order of 0.3 micron, for use in diagnostic pulmonary ventilation studies.
  • U.S. Pat. No. 5,603,314 discloses a filtration device suitable for reducing exhaled particles released by a patient during aerosol inhalation therapy.
  • U.S. Pat. Nos. 5,755,221 and 7,246,617 disclose inhaling devices.
  • U.S. Pat. No. 6,070,575 discloses a nozzle for aerosolizing a drug formulation, the nozzle includes a flexible membrane material having a plurality of pores, the pores have an exit aperture diameter in the range of about 0.5 to about 50 microns.
  • US 2002/0073991 discloses a method of monitoring aerosol delivery efficacy.
  • US 2007/0175476 discloses an aerosol powder delivery device.
  • SUMMARY
  • The following embodiments and aspects thereof are described and illustrated in conjunction with systems, tools and methods which are meant to be exemplary and illustrative, not limiting in scope. In various embodiments, one or more of the above-described problems have been reduced or eliminated, while other embodiments are directed to other advantages or improvements.
  • In some embodiments, there is provided a nebulizer for producing aerosol, comprising a porous medium, wherein the porous medium is rigid, has two flat sides and further comprises: a plurality of pores; a liquid partially adsorbed in the porous medium; and gas, wherein the gas is caged in pores that are vacant of said liquid, wherein the porous medium is configured to act as a pneumatic multi-nozzle atomizing system.
  • In some embodiments, the nebulizer further comprising a mouthpiece configured to deliver the aerosol to the lungs of a subject by inhalation.
  • In some embodiments, the aerosol comprises droplets of the liquid, the droplets having an MMAD within the range of 0.3 to 7 microns. In some embodiments, the diameter of said droplets is in the range 0.3 to 1.1 micrometer. In some embodiments, the droplets are having a Geometric Standard Diameter (GSD) within the range of about 2-5 micrometer
  • In some embodiments, the diameter of the pores in the porous medium is below 1 micrometer.
  • In some embodiments, the porous medium contains at least 10% liquid contents.
  • In some embodiments, the porous medium has a modulus of rigidity of at least 10 GPa at 25° C.
  • In some embodiments, the porous medium comprises a metal.
  • In some embodiments, the nebulizer further comprises a chamber and a path, wherein the path is configured to receive the aerosol from the porous medium and transfer said aerosol to the chamber.
  • In some embodiments, the nebulizer further comprises means configured for creating a pressure drop between the two flat sides of the porous medium, said means are selected from a piston and a spring, and a vacuum pump. In some embodiments, the means for creating the pressure drop include a piston and a spring connected to the piston, and wherein said means are configured to generate at least two different magnitudes of said pressure drop.
  • In some embodiments, the nebulizer further comprises a fixture, the fixture comprises a fixture notch, wherein the piston comprises a plurality of piston slots, wherein the fixture notch is configured to adapt to any one of the plurality of piston slots, thereby compressing the spring at a plurality of heights.
  • In some embodiments, the liquid comprises a pharmaceutical composition.
  • In some embodiments, the porous medium is disposable.
  • In some embodiments, the pressure drop is within the range of 600 to 900 mbar.
  • In some embodiments, the aerosol is ultra-fine highly concentrated aerosol comprising at least 109-1011 droplets per cm3.
  • In some embodiments, there is provided a method for treating a disease or disorder related to the respiratory system in a subject in need thereof, comprising, administering to the subject a pharmaceutical composition for treatment of said disease or disorder by inhalation, using the nebulizer disclosed herein.
  • In some embodiments, the diameter of the pores of the porous medium is below 1 micrometer.
  • In some embodiments, there is provided a method for producing aerosol, comprising the steps of
  • providing the nebulizer disclosed herein; and
  • generating a pressure drop across the porous medium, thereby obtaining aerosol.
  • In some embodiments, the nebulizer further comprises a mouthpiece.
  • In some embodiments, the nebulizer further comprises a chamber and a path, and the method further comprising the steps of
  • transferring the aerosol from the porous medium and to the chamber through the path; and
  • storing the aerosol in the chamber.
  • In some embodiments, the method further comprises the step of positioning the mouthpiece in a position that exposes the aerosol in the chamber to the outer environment.
  • In some embodiments, there is provided a method for producing aerosol, comprising the steps of
  • providing the nebulizer as disclosed herein, the nebulizer comprise means for creating the pressure drop include a piston and a spring connected to the piston, and wherein said means are configured to generate at least two different magnitudes of said pressure drop, and further comprises a fixture, the fixture comprises a fixture notch, wherein the piston comprises a plurality of piston slots, wherein the fixture notch is configured to adapt to any one of the plurality of piston slots, thereby compressing the spring at a plurality of heights;
  • electing a piston slot from the plurality of piston slots;
  • engaging the fixture notch with the elected piston slot, thereby compressing the spring to a height corresponding to said piston slot, generating a pressure drop across the porous medium (by releasing the fixture notch from the piston slot) and producing aerosol, wherein the pressure drop being proportional to the height of the elected piston slot.
  • Certain embodiments of the present disclosure may include some, all, or none of the above advantages. One or more technical advantages may be readily apparent to those skilled in the art from the figures, descriptions and claims included herein. Moreover, while specific advantages have been enumerated above, various embodiments may include all, some or none of the enumerated advantages.
  • In addition to the exemplary aspects and embodiments described above, further aspects and embodiments will become apparent by reference to the figures and by study of the following detailed descriptions.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • Examples illustrative of embodiments are described below with reference to figures attached hereto. In the figures, identical structures, elements or parts that appear in more than one figure are generally labeled with a same numeral in all the figures in which they appear. Alternatively, elements or parts that appear in more than one figure may be labeled with different numerals in the different figures in which they appear. Dimensions of components and features shown in the figures are generally chosen for convenience and clarity of presentation and are not necessarily shown in scale. The figures are listed below.
  • FIG. 1 schematically illustrates a cross section of a porous medium, in accordance with some embodiments;
  • FIG. 2a schematically illustrates a cross-section of a nebulizer with a porous medium, in accordance with some embodiments;
  • FIG. 2b schematically illustrates a cross-section of a nebulizer with a porous medium, in accordance with some embodiments;
  • FIG. 2c schematically illustrates a cross-section of a nebulizer with a porous medium, in accordance with some embodiments;
  • FIG. 2d schematically illustrates a cross-section of a nebulizer with a porous medium, in accordance with some embodiments;
  • FIG. 3 schematically illustrates a cross-section of a nebulizer with a porous medium, in accordance with some embodiments.
  • DETAILED DESCRIPTION
  • In the following description, various aspects of the disclosure will be described. For the purpose of explanation, specific configurations and details are set forth in order to provide a thorough understanding of the different aspects of the disclosure. However, it will also be apparent to one skilled in the art that the disclosure may be practiced without specific details being presented herein. Furthermore, well-known features may be omitted or simplified in order not to obscure the disclosure.
  • The proposed technology is intended for creating ultra-fine aerosol, which is specifically beneficial for delivering pharmaceutically active ingredients to the lungs, including the alveoli, of a subject in need of a treatment to their respiratory system, through inhalation. Generally, the formation of ultra-fine aerosol (typically, 0.3 to 1.1 micrometer of droplet size of the aerosol) is achieved by using rigid porous material into which a liquid comprising the pharmaceutically active ingredients, is partially adsorbed. The porous medium acts as a pneumatic multi-nozzle atomizing system.
  • In some embodiments, there is provided a nebulizer for producing aerosol, comprising a porous medium, wherein the porous medium is rigid, has two flat sides and further comprises: a plurality of pores; a liquid partially adsorbed in the porous medium; and gas, wherein the gas is caged in pores that are vacant of said liquid, and wherein the porous medium is configured to act as a pneumatic multi-nozzle atomizing system.
  • The nebulizer disclosed herein may function as an inhaler under some circumstances. Thus, the terms ‘nebulizer’ and ‘inhaler’ as used herein may be interchangeable.
  • Advantageously, the nebulizer disclosed herein prevents accumulation or formation “dead” volume of atomized liquid, during aerosol generation, which cannot be sprayed as aerosol.
  • An additional benefit of the nebulizer disclosed herein is that it may be used (held) in any orientation, during its operation. The formation of aerosol in the required dosage is not affected by the position or orientation of the nebulizer, during usage.
  • Furthermore, unlike use of a mask, tent or any disperser, use of the nebulizer disclosed herein does not involve medicine leakage. Thus, use of the nebulizers disclosed herein is safer and effective to the patients and the environment.
  • Another advantage conferred by use of the nebulizer is that no heating nor ultrasonic energy is required for its operation. Thus, the nebulizer is safe and effective for any pharmaceuticals, including heat/radiation sensitive pharmaceutical compositions.
  • In some embodiments, the nebulizer is configured to deliver the aerosol to the lungs by inhalation. In some embodiments, the nebulizer is configured to deliver the aerosol to a subject's lungs by inhalation. In some embodiments, the nebulizer is configured to prevent substantially the delivery of the aerosol to subject's nose and/or throat.
  • The correlation between droplet size and deposition thereof in the respiratory system has been established. It is generally known in the art that large droplets which are intended for delivery of therapeutics to the nose and throat, and not to the lungs, should be in the size of above 5 micrometers in diameter (see, for example, Natural Ventilation for Infection Control in Health-Care Settings, Atkinson et al. World Health Organization 2009, p. 103 lines 15-18). Droplets around 10 micron in diameter are suitable for deposition in the oropharynx and the nasal area; while droplets around 2-4 micron in diameter are suitable for deposition in the central airways, including the lungs, alveoli, bronchi and alveolar ducts. As a result, a nebulizer configured for producing aerosol having a diameter lower than 5 micrometer may enhance lung congestion at the expense of delivery to the nose and/or throat.
  • As used herein, the term “respiratory system” refers to the system of organs in the body responsible for the intake of oxygen and the expiration of carbon dioxide. The system generally includes all the air passages from the nose to the pulmonary alveoli. In mammals it is generally considered to include the lungs, bronchi, bronchioles, trachea, nasal passages, and diaphragm.
  • In some embodiments, the aerosol comprises droplets. In some embodiments, the aerosol comprises droplets of the liquid. In some embodiments, the nebulizer produces the aerosol from the liquid.
  • It was found that nebulization of liquids using nebulizers as disclosed herein, results in droplets having a mass median aerodynamic diameter (MMAD) sufficiently small so as to reach the lungs, rather than precipitate on their way thereto. The small droplets reaching the lungs enable efficient respiratory delivery of therapeutic agents in the aerosolized liquid. This is an overall advantage as maximizing the delivery of therapeutic agents to the lungs, while minimizing their deposition in the mouth and throat are important in treating diseases or disorders related to the respiratory system.
  • The terms ‘droplet size’ and ‘mass median aerodynamic diameter’, also known as MMAD, as used herein are interchangeable. MMAD is commonly considered as the median particle diameter by mass. MMAD may be evaluated by plotting droplet size vs. the cumulative mass fraction (%) in the aerosol. MMAD may then be determined according to the interpolated droplet size corresponding to the point, where the cumulative mass fraction is 50%. This point represents the estimated values of particle sizes, above which the droplets are responsible to half to masses and below, which the droplets are responsible to the other halves, in each solution.
  • In some embodiments, the MMAD is within the range of 2 to 10 microns. In some embodiments, the aerosol comprises droplets having an MMAD of less than 10 microns. In some embodiments, the aerosol comprises droplets having an MMAD within the range of 0.3 to 7 microns. In some embodiments, the MMAD is less than 5 microns.
  • In some embodiments, the diameter of the droplets is in the range 0.1 to 2.5 micrometer. In some embodiments, the diameter of the droplets is in the range 0.1 to 1.5 micrometer. In some embodiments, the diameter of the droplets is in the range 0.3 to 1.1 micrometer. In some embodiments, the diameter of the droplets is in the range 0.5 to 1.0 micrometer.
  • In some embodiments, the aerosol comprises droplets having a Geometric Standard Diameter (GSD) within the range of about 0.4-7 micrometer. In some embodiments, the aerosol comprises droplets having a GSD within the range of about 2-5 micrometer.
  • In some embodiments, the diameter of the pores in the porous medium is below 2 micrometer. In some embodiments, the diameter of the pores in the porous medium is below 1 micrometer. In some embodiments, the diameter of the pores in the porous medium is below 0.75 micrometer. In some embodiments, the diameter of the pores in the porous medium is below 0.5 micrometer. In some embodiments, the diameter of the pores in the porous medium is below 0.25 micrometer. In some embodiments, the diameter of the pores in the porous medium is below 0.1 micrometer.
  • The term “partially absorbed” as used herein refers to the percentage of liquid absorbed in the pores of the porous medium, wherein 0% refers to a porous medium where all of its pores are vacant of liquid. Thus, the term “partially absorbed” may refer to a porous medium wherein at least 0.005% of the pores contain liquid, or wherein the overall contents of the vacant space within the porous medium occupied with liquid is 0.005%. In some embodiments, partially absorbed refers to at least 0.001% liquid contents within the porous medium. In some embodiments, partially absorbed refers to at least 0.05% liquid contents within the porous medium. In some embodiments, partially absorbed refers to at least 0.01% liquid contents within the porous medium. In some embodiments, partially absorbed refers to at least 0.5% liquid contents within the porous medium. In some embodiments, partially absorbed therein refers to at least 0.1% liquid contents within the porous medium. In some embodiments, partially absorbed refers to at least 1% liquid contents within the porous medium. In some embodiments, partially absorbed refers to at least 5% liquid contents within the porous medium. In some embodiments, partially absorbed refers to at least 10% liquid contents within the porous medium. In some embodiments, partially absorbed refers to at least 20% liquid contents within the porous medium. In some embodiments, partially absorbed refers to at least 30% liquid contents within the porous medium. In some embodiments, partially absorbed refers to at least 40% liquid contents within the porous medium. In some embodiments, partially absorbed refers to at least 50% liquid contents within the porous medium.
  • In some embodiments, the term “partially absorbed” may refer to the content of liquid within the volume of pores located on the surface and in the immediate vicinity of the surface (sub surface) of a porous medium. In some embodiments, the volume of the sub-surface may extend from the surface to a depth of about 50 micron from the surface.
  • In some embodiments, partially absorbed refers to a porous medium wherein at least 0.5% of the surface and sub-surface pores contain liquid. In some embodiments, partially absorbed refers to at least 1% liquid contents within the surface and sub-surface pores. In some embodiments, partially absorbed refers to at least 10% liquid contents within the surface and sub-surface pores. In some embodiments, partially absorbed refers to at least 20% liquid contents within the surface and sub-surface pores. In some embodiments, partially absorbed refers to at least 30% liquid contents within the surface and sub-surface pores. In some embodiments, partially absorbed refers to at least 40% liquid contents within the surface and sub-surface pores. In some embodiments, partially absorbed refers to at least 50% liquid contents within the surface and sub-surface pores. In some embodiments, partially absorbed refers to at least 60% liquid contents within the surface and sub-surface pores.
  • In some embodiments, the porous medium is rigid when liquid is partially adsorbed therein.
  • The term “rigid” as used herein characterizes materials that are generally non-flexible, and do not undergo deformation in response to an applied force. Specifically, a porous medium that is rigid, does not bend or otherwise deforms upon ejection of liquid droplets therethrough. Rigidity is typically measured in pressure units, through parameters such as Modulus of Rigidity (G; Shear Modulus) or Young's modulus. Rigidity of materials may be dependent on environments features. For example, cellulose may exhibit a rigid structure in a dry form, however, when adsorbed in liquid cellulose cannot maintain a dry rigid structure, but rather becomes flexible. Glass and most metals are rigid in a wide range of temperature, including at room temperature, but become flexible in extremely high temperatures.
  • In some embodiments, the rigid porous medium does not substantially change its rigidity upon adsorption of liquids therein. In some embodiments, the rigidity of the rigid porous medium is not substantially effected upon being in contact with liquids.
  • In some embodiments, porous medium is made of a rigid material, wherein the rigidity of the rigid material is not substantially effected by contact with liquids.
  • In some embodiments, the porous medium has a modulus of rigidity of at least 10 GPa (109 pascal) at 25° C. In some embodiments, the porous medium has a modulus of rigidity of at least 15 GPa at 25° C. In some embodiments, the porous medium has a modulus of rigidity of at least 20 GPa at 25° C. In some embodiments, the porous medium is substantially devoid of materials having modulus of rigidity lower than 10 GPa at 25° C.
  • As used herein, the terms “substantially effected” and “substantially change”, when referring to the rigidity of materials, are intended to include changes of more than 10% in the modulus of rigidity of the material. For example, for a dry porous medium having a modulus of rigidity of 50 GPa, the phrase “the rigidity of the porous medium is not substantially effected by contact with liquids” means that upon contact with liquids, the modulus of rigidity of the material will remain in the range of 45 GPa to 55 GPa.
  • In some embodiments, the porous medium is made of a material selected from the group consisting of metals and metal alloys. In some embodiments, the porous medium comprises a metal. In some embodiments, the porous medium is made of metal. In some embodiments, the porous medium comprises polymers.
  • It is to be understood that a polymer used for forming the porous medium is typically a rigid polymer, such as, a polymer having a Tg (glass transition temperature) in the range of 100 or above 100.
  • In some embodiments, the porous medium comprises materials selected from the group consisting of aluminum, cobalt, copper, iron, magnesium, nickel, silicon, steel, titanium, polymers, including alloys and combinations thereof.
  • In some embodiments, the porous medium is rigid and has two flat sides. It is to be understood that, due to the rigidity of the porous medium, it remains flat throughout the operation of the nebulizer. As defined above, a rigid medium is resistant to deformation upon application of external force. Therefore, the medium does not curve into a concave or convex shape, rather it remains flat during operation of the nebulizer, and specifically, during formation of aerosol.
  • In some embodiments, the nebulizer further comprises a chamber and a path, wherein the path is configured to receive the aerosol from the porous medium and transfer said aerosol to the chamber.
  • In some embodiments, the nebulizer further comprises an outlet, also referred to as exit hole. In some embodiments, the outlet is configured to release said aerosol by inhalation. In some embodiments, the outlet is configured to deliver said aerosol to the lungs by inhalation.
  • In some embodiments, the nebulizer further comprises a cover configured to fix the porous medium to the body of the nebulizer.
  • In some embodiments, the cover further comprises a duct extended between the cover and the external environment.
  • In some embodiments, the duct is open, such that the internal environment of the nebulizer is exposed to the atmospheric pressure. Without being bound by any theory or mechanism, by maintaining the duct open, the internal pressure within the nebulizer reaches a steady state of atmospheric pressure.
  • In some embodiments, the nebulizer further comprises means for creating a pressure drop between the two flat sides of the porous medium. In some embodiments, the nebulizer further comprises an element configured for creating a pressure drop between the two flat sides of the porous medium. In some embodiments, the element comprises a piston and a spring. In some embodiments, the element further comprises a vacuum pump. In some embodiments, the element further comprises a piston, a spring and vacuum pump.
  • In some embodiments, creating a pressure drop between the two flat sides of the porous medium is achieved by introducing pressurized air to one flat side of the porous medium. In some embodiments, creating a pressure drop between the two flat sides of the porous medium comprises introducing vacuum or sub-atmospheric pressure near one flat side of the porous medium. In some embodiments, creating a pressure drop between (or across) the two flat sides of the porous medium comprises generating or having a pressure difference between the two flat sides (or flat surfaces) of the rigid porous medium. In some embodiments, the pressure difference is in the range of 600 mbar to 900 mbar.
  • In some embodiments, prior to the pressure drop, the pressure across the porous medium is an atmospheric pressure. In some embodiments, the pressure drop across the porous medium is within the range of 500 to 990 mbar. In some embodiments, the pressure drop is within the range of 600 to 900 mbar. In some embodiments, the pressure drop is within the range of 650 to 850 mbar.
  • In some embodiments, the porous medium is in a shape of a disc.
  • In some embodiments, the porous medium is in a shape of a pill.
  • In some embodiments, the porous medium is in a shape of a coin.
  • In some embodiments, the porous medium is in a shape of a cylinder.
  • In some embodiments, the nebulizer further comprises a tube connecting the chamber to said duct and configured to increase the pressure drop between the two flat sides of the porous medium.
  • In some embodiments, the nebulizer further comprises a fixture and a piston connected to a spring, the fixture comprising a fixture notch, and the piston comprising at least two piston slots located at different levels along the piston. In some embodiments, the fixture is connected to the peripheral surface of the outer structure, optionally through a joint, wherein the joint serves as a rotation axis and one end of the fixture is further attached to the peripheral surface of the outer structure in order to force the other end of the fixture, comprising the fixture notch, to be engaged with any one of the piston slots. In some embodiments, applying pressure to the fixture at the region of the fixture spring causes the fixture to rotate against the joint, thereby releasing (displacing) the fixture notch from any one of the piston slots. In some embodiments, the displacement of the fixture notch releases the spring along a given height, depending on the piston slot from which the fixture notch has been released. Thus, displacement of the fixture notch can release the spring along various heights, thereby generating different magnitudes of pressure drop across the porous medium for, depending on the position (level or height relative to the dimension of the nebulizer) of the piston slot. The terms “height” and “heights” as used herein generally refer to the distance between the bottom of the nebulizer's body (also termed outer structure 101 in FIGS. 2a-2d ) and the piston.
  • In some embodiments, the liquid comprises water. In some embodiments, the liquid comprises an aqueous pharmaceutically suitable carrier and at least one pharmaceutical active ingredient. In some embodiments, the liquid comprises an aqueous dispersion. In some embodiments, the liquid comprises any one of an aqueous solution, an aqueous emulsion, an aqueous suspension and an aqueous colloidal suspension.
  • In some embodiments, the liquid comprises a pharmaceutical composition.
  • As used herein, the term “pharmaceutical composition” is interchangeable with any of the terms “medication”, “drug” and the like, refers to a preparation of a composition comprising one or more pharmaceutically active agents, suitable for administration to a patient via the respiratory system.
  • In some embodiments, the liquid comprises a therapeutically effective amount of a pharmaceutical composition. In some embodiments, the liquid comprises a pharmaceutical composition for treatment or prevention of a disease or disorder of the respiratory system.
  • In some embodiments, the aerosol comprises a pharmaceutical composition. In some embodiments, the aerosol comprises a therapeutically effective amount of the pharmaceutical composition. In some embodiments, the aerosol comprises a pharmaceutical composition for treatment or prevention of a disease or disorder of the respiratory system.
  • As used herein, the term “therapeutically effective amount” refers to a pharmaceutically acceptable amount of the pharmaceutical composition, or the pharmaceutical active ingredient(s), which prevents or ameliorates, at least partially, the symptoms signs of a particular pulmonary or respiratory disease or disorder, in a living organism to whom it is administered over some period of time.
  • In some embodiments, the pharmaceutical composition is for the treatment of a respiratory disease or disorder. In some embodiments, the disease or disorder is selected from the group consisting of asthma, bronchitis, emphysema, lung infection, cystic fibrosis, AAT deficiency, COPD, ARDS, IRDS, BPD, and MAS. Each possibility is a separate embodiment of the invention.
  • In some embodiments, the disease or disorder is affecting the airways, the alveoli or the interstitium, such as, asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema, acute bronchitis, cystic fibrosis, pneumonia, tuberculosis, fragile connections between alveoli, pulmonary edema, lung cancer in its many forms, acute respiratory distress syndrome, pneumoconiosis, mouth and pharynx cancer, tracheal tumors and interstitial lung disease among others.
  • As used herein the term “aerosol” or “aerosolized agent” refers to a suspension of solid or liquid particles of the agent in a gas. As used herein “aerosol” or “aerosolized agent” may be used generally to refer to an agent, including, a pharmaceutically active agent, that has been vaporized, nebulized, or otherwise converted from a solid or liquid form to an inhalable form including suspended solid or liquid drug particles.
  • In some embodiments, the liquid further comprises at least one pharmaceutical acceptable carrier. In some embodiments, the liquid may further comprise one or more stabilizers.
  • In some embodiments, the liquid further comprises a sweetener. In some embodiments, the sweetener is selected from the group of artificial sweeteners including saccharine, aspartame, dextrose and fructose.
  • In some embodiments, the liquid further comprises at least one anti-coughing agent.
  • The term “anti-coughing agent” as used herein refers to an active agent used for the suppression, alleviation or prevention of coughing and irritations and other inconveniencies in the large breathing passages that can, or may, generate coughing. Anti-coughing agent include, but are not limited to antitussives, which are used for which suppress coughing, and expectorants, which alleviate coughing, while enhancing the production of mucus and phlegm. Anti-coughing agents may ease the administration of inhaled aerosols.
  • In some embodiments, the at least one anti-coughing agent is selected from expectorants, antitussives or both. In some embodiments, the at least one anti-coughing agent is selected from the group consisting of menthol, dextromethorphan, dextromethorphan hydrobromide, hydrocodone, caramiphen, dextrorphan, 3-methoxymorphinan or morphinan-3-ol, carbetapentane, codeine, acetylcysteine and combinations thereof.
  • In some embodiments, the liquid further comprises at least one preservative. In some embodiments, the preservative is selected from the group consisting of benzyl alcohol, propylparaben, methylparaben, benzalkonium chloride, phenyl ethyl alcohol, chlorobutanol, potassium sorbate, phenol, m-cresol, o-cresol, p-cresol, chlorocresol and combinations thereof.
  • In some embodiments, the porous medium is disposable.
  • In some embodiment, the porous medium is configured to multiple uses. It is to be understood, that multiple use may require washing the porous medium between uses.
  • In some embodiments, the nebulizer is mobile. In some embodiments, the nebulizer is portable. In some embodiments, the nebulizer is handheld. In some embodiments, the nebulizer is powered by a mobile power source.
  • In some embodiments, the nebulizer is configured to communicate with servers, databases, personal devices (computers, mobile phones) among others.
  • In some embodiments, the nebulizer is configured to communicate wirelessly with servers, databases, personal devices (computers, mobile phones) among others.
  • In some embodiments, the nebulizer further comprises at least one tubular opening, also termed herein “mouthpiece” configured to deliver the aerosols to a respiratory system of a subject, and an outer structure opening configured to expose the contents of the chamber to the mouthpiece. In some embodiments, the mouthpiece extends outwardly from the lower peripheral surface of the outer structure towards the environment outside the nebulizer, or towards the user. In some embodiments, the mouthpieces is, configured to rotate around said peripheral surface from a first opening position to a second opening position. In first opening position the mouthpiece is positioned against a wall of the outer structure, where in second opening position the mouthpiece is positioned against the outer structure opening. In first opening position, both the mouthpiece and the outer structure opening are blocked, such that the mouthpiece is exposed to the outer environment but blocked by the wall of the outer structure to the contents of the chamber. Similarly, the outer structure opening is blocked from the outer environment. Blocking of the outer structure can be, for example by means of a ring. In some embodiments, the ring is connected to the mouthpiece and is configured to rotate around the periphery of the outer structure, the ring being open only at the region of connection with the mouthpiece. In the second opening position, the aerosol contained within the chamber is exposed, through the outer structure opening, followed by the mouthpiece, to the outer environment.
  • In some embodiments there is provided a method of delivering a pharmaceutical composition to a subject by inhalation, the method comprising administering the pharmaceutical composition to the subject using the nebulizer disclosed herein.
  • In some embodiments there is provided a method of delivering a pharmaceutical composition to a subject in need thereof by inhalation, the method comprising administering the pharmaceutical composition to the subject using the nebulizer disclosed herein.
  • In some embodiments, administering the pharmaceutical composition to the subject comprises delivering the pharmaceutical composition in the form of aerosols to the respiratory system of the subject.
  • In some embodiments, the subject in need thereof is a subject afflicted with respiratory disease or disorder.
  • In some embodiments there is provided a porous medium configured to act as a pneumatic multi-nozzle atomizing system, wherein the porous medium is rigid, has two flat sides and further comprises a plurality of pores; a liquid partially adsorbed in the porous medium; and gas, wherein the gas is caged in pores that are vacant of said liquid.
  • In some embodiments, the porous medium is configured to release an aerosol. In some embodiments, the aerosol comprises droplets. In some embodiments, the aerosol comprises droplets of the liquid.
  • In some embodiments, the MMAD is within the range of 2 to 10 microns. In some embodiments, the aerosol comprises droplets having an MMAD of less than 10 microns. In some embodiments, the aerosol comprises droplets having an MMAD within the range of 0.3 to 7 microns. In some embodiments, the MMAD is less than 5 microns. In some embodiments, the diameter of the droplets is in the range 0.1 to 2.5 micrometer. In some embodiments, the diameter of the droplets is in the range 0.1 to 1.5 micrometer. In some embodiments, the diameter of the droplets is in the range 0.3 to 1.1 micrometer. In some embodiments, the diameter of the droplets is in the range 0.5 to 1.0 micrometer. In some embodiments, the aerosol comprises droplets having a Geometric Standard Diameter (GSD) within the range of about 0.4-7 micrometer. In some embodiments, the aerosol comprises droplets having a GSD within the range of about 2-5 (two to five) micrometer.
  • In some embodiments, the porous medium is in a flat shape selected from the group consisting of: cylinder, ring, disc and coin.
  • In some embodiments, the liquid comprises a pharmaceutical composition. In some embodiments, the aerosol comprises a pharmaceutical composition for treatment of a disease or disorder of the respiratory system. In some embodiments, the pharmaceutical composition is intended for delivery to the lungs.
  • In some embodiments, there is provided a method for producing ultra-fine highly concentrated aerosol, comprising providing the nebulizer disclosed herein and inducing a pressure drop between the two flat sides of the porous medium, thereby producing aerosol.
  • In some embodiments, inducing a pressure drop between the two flat sides of the porous medium comprises introducing pressurized air to one flat side of the porous medium.
  • In some embodiments, inducing a pressure drop between the two flat sides of the porous medium comprises introducing vacuum or sub-atmospheric pressure near one flat side of the porous medium.
  • In some embodiments, inducing a pressure drop between the two flat sides of the porous medium comprises connecting the nebulizer to a pump.
  • In some embodiments, inducing a pressure drop between the two flat sides of the porous medium comprises displacing the piston. In some embodiments, inducing a pressure drop between the two flat sides of the porous medium comprises manually displacing the piston. In some embodiments, the outer structure includes an elongated slot through which an extension arm, connected to the piston, protrudes outwardly. In some embodiments the extension arm is displaced in the elongated direction along the outer structure, such that manual displacement of said extension arm, for example by the user's hand, in the upward or downward direction, displaces the piston located in the chamber of the outer structure in the same direction. In that manner, after the release of the piston and its movement downward by the force exerted by the spring, as described hereinabove, the user is able to manually push the extension arm upwards while compressing the fixture spring, releasing the fixture when the fixture notch is placed against the desired height level of the piston slot, rendering the nebulizer ready for reuse.
  • The term “concentrated aerosol” as used herein refers to the number of droplets per volume unit. Concentrated aerosols include more than 108 droplets per cm3. Highly concentrated aerosol includes more than 109 droplets per cm3.
  • In some embodiments, the aerosol includes more than 109 droplets per cm3. In some embodiments, the aerosol includes more than 109-1011 droplets per cm3.
  • In some embodiments, inducing the pressure drop is achieved by inducing a pressure drop on one side of said two flat sides of the porous medium.
  • In some embodiments, inducing the pressure drop is achieved by vacuum generating means comprising a piston.
  • In some embodiments, pressure drop across the porous medium is within the range of 500 to 990 mbar; 600 to 900 mbar; or 650 to 850 mbar.
  • In some embodiments, the method further comprises storing the aerosol in the chamber.
  • In some embodiments, the method further comprises storing the aerosol in the chamber under vacuum.
  • In some embodiments, the aerosol is transferred under vacuum in the chamber for storage.
  • Reference is now made to FIG. 1, which schematically illustrates a cross section of porous medium 102. Porous medium 102 comprises rigid porous material 1, pores 2, liquid 3 and gas 4, according to some embodiments.
  • Liquid 3 is contained within some of pores 2 of porous medium 102, according to some embodiments. It is intended for spraying from a nebulizer, such as nebulizer 100 of FIGS. 2a-2d , which includes porous medium 102, according to some embodiments. Liquid 3 is partially absorbed in porous material 1, according to some embodiments. Liquid 3 includes an aqueous pharmaceutical composition, comprising medication for the treatment of a pulmonary disease, and is intended for spraying through a nebulizer into the lungs, according to some embodiments.
  • Pores 2 are being cavities within rigid porous material 1, according to some embodiments. Pores 2 are of sub-micron size, i.e. their median diameter is below 1 micrometer, according to some embodiments. Pores 2 are partially adsorbed by liquid 3 and partially filled with gas 4, according to some embodiments. Pores 2 are acting as nozzles, according to some embodiments.
  • Gas 4 is caged in some of pores 2, which are vacant of liquid 3, according to some embodiments.
  • Porous material 1 form the body of porous medium 102, according to some embodiments. It is a rigid metallic material, which is shaped as a coin, according to some embodiments. Porous material 1 has structure and dimensions, which are determined according to the required aerosol characteristics for each required application, according to some embodiments. For example, the dispersing area of porous material 1 (i.e. the surface area, or one side, of porous material 1) determines the quantity of achieved aerosol. The greater the surface area, the more aerosol is produced, per use. Reference is now made to FIGS. 2a-2d , which schematically illustrate cross-sectional views of a nebulizer 100 comprising porous medium 102, according to some embodiments. Specifically, FIGS. 2a-c illustrate nebulizer 100 comprising porous medium 102, in different stages: FIGS. 2a-2b illustrate nebulizer 100 comprising porous medium 102 prior to aerosol production, in a first optional compressed position and a second optional compressed position, respectively; FIG. 2c illustrates nebulizer 100 comprising porous medium 102 when nebulizer 100 is in aerosol production position, due to the pressure drop generated between upper flat side 102 b and lower flat side 102 a of the porous medium 102; and FIG. 2d describes nebulizer 100 comprising porous medium 102 in a position that enables aerosol inhalation.
  • Nebulizer 100 is configured to transform liquid 3 to an aerosol, according to some embodiments. The aerosol spraying is performed by instantaneously inducing pressure drop across the thickness of porous medium 102, according to some embodiments. Since porous medium 102 is has a thickness and two flat sides, the differential pressure occurs between the two flat sides of porous medium 102, according to some embodiments. When porous medium 102 is in atmospheric pressure, a pressure drop is induced across porous medium 102, creating a low pressure at one side of porous medium 102, compared to the atmospheric pressure on the other side of porous medium 102, according to some embodiments. According to some embodiments, the size of the pressure drop may be in the range of 600 to 900 mbar. Nebulizer 100 being under a pressure drop across porous medium 102 is illustrated in FIG. 2c . At this stage, atomization occurs as a result of the pressure difference across the two sides of porous medium 102, according to some embodiments. The pressure difference causes the medium to act as a pneumatic multi-nozzle, where the nozzles are defined by pores 2 of porous medium 102, according to some embodiments.
  • Without wishing to be bound by any theory or mechanism of action, the effect of pneumatic multi-nozzle atomization is the result of gas 4, which is caged in the internal volume of porous medium 102, being released in the direction of vacuum or low pressure. Gas 4 release causes pores 2 to act as nozzles and spray liquid 3 outside porous medium 102. The aerosol is then achieved on the side of the lower pressure—bottom flat side 102 a, as illustrated in FIG. 2a . This mechanism of nebulizing action does not require an external gas supply in order to achieve aerosol formation.
  • The pressure drop is the result of the difference between an atmospheric pressure above porous medium 102 and the lower pressure generated in the chamber below porous medium 102, also referred to as aerosol accumulator, or vacuum accumulator 101 a. Vacuum accumulator 101 a is also used for storing the aerosol, after being produced, until the aerosol is required for use (i.e. inhalation), according to some embodiments.
  • According to some embodiments, the low pressure generated in the aerosol accumulator (vacuum accumulator 101 a) is sub-atmospheric pressure.
  • According to some embodiments, the low pressure generated in aerosol accumulator (vacuum accumulator 101 a) is vacuum or negative pressure.
  • Vacuum accumulator 101 a may also be used as a drying chamber depending on the relation between the volume of accumulator 101 a and the quantity of the droplets, and further depending on the overall parameters of the environment inside vacuum accumulator 101 a, according to some embodiments. Such parameters include temperature and pressure. Upon using chamber 101 a for drying, dry aerosol is obtained by nebulizer 100, according to some embodiments.
  • In addition, drying process can take place by the act of inhalation itself, when the inhaled air acts as drying agent, according to some embodiments.
  • Nebulizers comprising porous medium 102, such as nebulizer 100, operate in many different environments and any positions, such as, in an upright and horizontal position, according to some embodiments.
  • According to some embodiments, nebulizer 100 may be self-sustained, i.e. the pressure drop is created inherently and not by connecting nebulizer 100 to a pump.
  • Porous medium 102 may also be used as a storage container for liquid 3 prior to the conversion of liquid 3 to aerosol, according to some embodiments. Porous medium 102 as a storage container may include porous medium 102 soaked with a pre-determined quantity of liquid 3, according to some embodiments.
  • According to some embodiments, porous medium 102 is soaked with a pre-determined quantity of liquid 3, forming a ready for use “pill”. According to some embodiments, the pill is hermetically and sterilely sealed and packed.
  • According to some embodiments, porous medium 102 is packed together with a container containing liquid 3, where in between porous medium 102 and the container, there is a buffer layer impermeable to liquids. This packing forms a “sandwich” like device. Upon removal of the buffer layer, porous medium 102 absorbs liquid 3. According to some embodiments, removal of the buffer layer from the sandwich pack is performed prior to use of nebulizer 100 or porous medium 102, i.e. before the atomizing effect takes place in order to perform aerosol.
  • According to some embodiments, the sandwich is sealed and packed. In some embodiments, the sandwich is disinfected and sterilized prior to being sealed and packed.
  • According to some embodiments, porous medium 102 is designed to be used with specific nebulizer devices, and may be adapted to use with any nebulizer, if required.
  • According to some embodiments, porous medium 102 is disposable.
  • According to some embodiments, porous medium 102 is configured for multiple uses. According to some embodiments, porous medium 102 is configured for discharge of, and replenishment with, liquid 3.
  • According to some embodiments, nebulizer 100 further comprises an outer structure 101. Outer structure 101 encompasses vacuum accumulator 101 a. The dimensions of vacuum accumulator 101 a are determined according to the volume of aerosol required for each application. According to some embodiments, to produce 30 mg of medical aerosol for local delivery to the lung or systematic delivery through the lung, a volume of at least 30 cc is required. Vacuum accumulator 101 a has a path 101 b through which the aerosol received from porous medium 102 enters vacuum accumulator 101 a.
  • Nebulizer 100 further comprise a mouth-piece, also termed opening or exit hole 103, a structure opening 101 d, cylinder piston 104, spring 105, cover 106 and duct 106 b, according to some embodiments. Exit hole 103 is utilized for aerosol inhalation by a user when it is positioned against the structure opening 101 d (see FIG. 2d ). Exit hole 103 is blocked when it is positioned against an external wall of the outer structure 101 (see FIGS. 2a-2c ). According to some embodiments, a vacuum or a low-pressure effect can be generated externally by a vacuum pump (e.g., for stationary use) or by an internal device included in the nebulizer itself. According to some embodiments, cylinder piston 104 is attached to spring 105, thereby displaced from one position wherein spring 105 is compressed (see FIGS. 2a-2b ) to other positions, towards the bottom of outer structure 101, when spring 105 is released (see FIG. 2c ). This movement of cylinder piston 104 results in a desired pressure drop, due to the vacuum or sub-atmospheric pressure generated in vacuum accumulator 101 a, needed for aerosol production, according to some embodiments. The upper side of nebulizer 100 comprises a grove (not numbered) configured for placement of porous medium 102, according to some embodiments. Porous medium 102 is fixed or sealed to the device by cover 106, designed for fast opening/closing, according to some embodiments. Cover 106 has duct 106 b extended between cover 106 and the external environment, according to some embodiments.
  • According to some embodiments, porous medium 102 may be located in any position within nebulizer 100. According to some embodiments, porous medium 102 is located at the upper side of nebulizer 100 (as shown in FIGS. 2a-2c ) but can also be located on the opposite (bottom side) or in any side of nebulizer 100.
  • FIG. 2a shows nebulizer 100 prepared for generation of aerosol, in accordance with some embodiments. Fixture 108 includes notch 108 a. The formation of notch 108 a enables fixture 108 to be engaged with piston slot 104 a in such a manner that piston 104 is maintained in a first optional compressed position. In this first optional position, spring 105 is compressed such that the distance between the lower edge of piston 104 and the bottom of vacuum accumulator 101 a is H1. Porous medium 102 is fixed to nebulizer 100 by cover 106; and exit hole 103 is blocked by outer structure 101.
  • FIG. 2b shows nebulizer 100 prepared for generation of aerosol, in accordance with some embodiments. Notch 108 a is engaged with piston slot 104 b in such a manner that piston 104 is maintained in a second optional compressed position. In this second optional position, spring 105 is compressed such that the distance between the lower edge of piston 104 and the bottom of the vacuum accumulator 101 a is H2.
  • It will be understood that piston 104 of nebulizer 100, prepared for generating aerosol, can be maintained either in first optional compressed position (see FIG. 2a ) or in a second optional compressed position (see FIG. 2b ), prior to the release of the spring 105.
  • In accordance with some embodiments, H1 and H2 are not equal. In accordance with some embodiments, H2 is longer than H1.
  • FIG. 2c shows nebulizer 100 in the instant right after the release of the fixture 108, also referred to as the stage of aerosol generation. Fixture 108 is designed as a lever, according to some embodiments, thereby configured to release notch 108 a from either piston slot 104 a or piston slot 104 b, when pressure is applied to the bottom portion of fixture 108, i.e. the portion of fixture 108 opposite to the location of notch 108 a. The displacement of notch 108 a releases piston 104, thereby releasing spring 105 from its compressed state, either at first optional compressed position or at second optional compressed position, to a released position. In the released position, spring 105 displaces piston 104 towards the bottom of outer structure 101, thereby creating vacuum or sub-atmospheric pressure, in vacuum accumulator 101 a. The pressure drop created across porous medium 102 generates aerosol within vacuum accumulator 101 a.
  • While fixture 108 illustrated in FIGS. 2a-2d is designed as a lever, it will be understood that fixture 108 may be formed to accommodate other methods known in the art for release of notch 108 a by a user.
  • Without wishing to be bound by any theory or mechanism of action, the magnitude of pressure drop across porous medium 102 is proportional to the initial distance between the lower edge of the piston 104 and the bottom of the vacuum accumulator 101 a, such that if distance H2 is longer than H1, the pressure in aerosol accumulator 101 a at the instant after spring 105 is released is lower in the case that piston 104 was positioned in the second optional compressed position, at height H2, compared to the case wherein piston 104 was positioned in the first optional compressed position, at height H1. Therefore, the former results in a higher pressure drop than the later. Thus, as there are more than one optional position for piston 104 prior to the release of spring 105 a range of different pressure drops can be generated. Thus, user of nebulizer 100 can choose pressure drops, based on the desired parameters of the resulting aerosol, such as, but not limited to: MMAD, GSD or aerosol concentration.
  • While FIGS. 2b-2c illustrate two piston slots 104 a and 104 b located at different levels, it will be understood that piston 104 may include any number of piston slots, thereby having any corresponding number of optional compressed positions, allowing an operator to choose between such positions in order to regulate the magnitude of the pressure drop across porous medium 102. FIG. 2d shows nebulizer 100 prepared for aerosol inhalation by a user: exit hole 103 is displaced to a position in front of structure opening 101 d, thereby exposing the contents of aerosol accumulator 101 a to the outside environment, allowing the aerosol to be nebulized by the user.
  • According to some embodiments, the aerosol within aerosol accumulator (or chamber, or vacuum accumulator 102 a) is stored in low pressure or in vacuum, wherein positioning outlet 103 in front of structure opening 101 d (see FIG. 2d ), exposes vacuum accumulator 101 a to the atmospheric pressure, rendering an equilibrium such that the pressure within vacuum accumulator 101 a is atmospheric as well, prior to inhalation by the user.
  • According to some embodiments, duct 106 b is kept open to the atmosphere. When low pressure is generated in aerosol accumulator 101 a at the first instant after the release of spring 105 (which is allowing generation of aerosol) air enters nebulizer 100 through duct 106 b, creating a new equilibrium of steady state in which the pressure within vacuum accumulator 101 a is atmospheric pressure.
  • Reference is now made to FIG. 3, which schematically illustrates nebulizer 200 comprising porous medium 102. Nebulizer 200 is similar in function and structure to nebulizer 100, and further comprises tube 109. Tube 109 is used for supply of air during the aerosol generation stage. Tube 109 extends from vacuum accumulator 101 a to duct 106 b, and delivers gas in that direction to increase aerosol capacity by increasing dispersing gas.
  • Without being bound by any theory or mechanism, introducing additional dispersing gas increases the magnitude of the pressure drop across porous medium 102.

Claims (20)

1. A nebulizer for producing aerosol, comprising a porous medium, wherein the porous medium is rigid, has two flat sides and further comprises: a plurality of pores; a liquid partially absorbed in the porous medium; and gas, wherein the gas is caged in pores that are vacant of said liquid, wherein the porous medium is configured to act as a pneumatic multi-nozzle atomizing system.
2. The nebulizer of claim 1, further comprising a mouthpiece configured to deliver the aerosol to the lungs of a subject by inhalation.
3. The nebulizer of claim 1, wherein the aerosol comprises droplets of the liquid, the droplets having a mass median aerodynamic diameter (MMAD) within the range of 0.3 to 7 microns.
4. The nebulizer of claim 3, wherein the diameter of said droplets is in a range of 0.3 to 1.1 micrometer.
5. The nebulizer of claim 1, wherein the diameter of the pores in the porous medium is below 1 micrometer.
6. The nebulizer of claim 1, wherein the overall contents of vacant space within the porous medium occupied with liquid is at least 10% liquid contents.
7. The nebulizer of claim 1, wherein the porous medium has a modulus of rigidity of at least 10 GPa at 25° C.
8. The nebulizer of claim 1, wherein the porous medium comprises a metal.
9. The nebulizer of claim 1, further comprising a chamber and a path, wherein the path is configured to receive the aerosol from the porous medium and transfer said aerosol to the chamber.
10. The nebulizer of claim 1, further comprising means configured for creating a pressure drop between the two flat sides of the porous medium, said means are selected from a piston and a spring, and a vacuum pump.
11. The nebulizer of claim 11, wherein the means for creating the pressure drop include a piston and a spring connected to the piston, and wherein said means are configured to generate at least two different magnitudes of said pressure drop.
12. The nebulizer of claim 1, wherein the liquid comprises a pharmaceutical composition.
13. The nebulizer of claim 1, wherein the porous medium is disposable.
14. The nebulizer of claim 11, wherein the pressure drop is within the range of 600 to 900 mbar.
15. The nebulizer of claim 1, wherein the aerosol is ultra-fine highly concentrated aerosol comprising at least 109-1011 droplets per cm3.
16. The nebulizer of claim 1, wherein the rigidity of the rigid porous medium is not substantially effected upon being in contact with liquids.
17. The nebulizer of claim 1, further comprising an outer structure blocking the mouthpiece, the outer structure having a structure opening, wherein in the first position, the mouthpiece is positioned against a wall of the outer structure, and in the second opening the mouthpiece is displaced to a position in front of the structure allowing the aerosol to be nebulized and administered to the subject.
18. A method for treating a disease or disorder related to the respiratory system in a subject in need thereof, comprising, administering to the subject a pharmaceutical composition for treatment of said disease or disorder by inhalation, using the nebulizer of claim 1.
19. The method of claim 18, wherein the diameter of the pores of the porous medium is below 1 micrometer.
20. A method for producing aerosol, comprising the steps of
a. providing the nebulizer of claim 1; and
b. generating a pressure drop across the porous medium, thereby obtaining aerosol.
US17/089,184 2010-01-12 2020-11-04 Method and apparatus for producing fine concentrated aerosol Abandoned US20210046258A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/089,184 US20210046258A1 (en) 2010-01-12 2020-11-04 Method and apparatus for producing fine concentrated aerosol

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29416110P 2010-01-12 2010-01-12
PCT/IL2011/000038 WO2011086552A1 (en) 2010-01-12 2011-01-12 A method and apparatus for producing fine concentrated aerosol
US201213521718A 2012-07-11 2012-07-11
US15/467,527 US10857311B2 (en) 2010-01-12 2017-03-23 Method and apparatus for producing fine concentrated aerosol
US17/089,184 US20210046258A1 (en) 2010-01-12 2020-11-04 Method and apparatus for producing fine concentrated aerosol

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/467,527 Continuation US10857311B2 (en) 2010-01-12 2017-03-23 Method and apparatus for producing fine concentrated aerosol

Publications (1)

Publication Number Publication Date
US20210046258A1 true US20210046258A1 (en) 2021-02-18

Family

ID=59236188

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/467,527 Active 2032-12-30 US10857311B2 (en) 2010-01-12 2017-03-23 Method and apparatus for producing fine concentrated aerosol
US17/089,184 Abandoned US20210046258A1 (en) 2010-01-12 2020-11-04 Method and apparatus for producing fine concentrated aerosol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/467,527 Active 2032-12-30 US10857311B2 (en) 2010-01-12 2017-03-23 Method and apparatus for producing fine concentrated aerosol

Country Status (1)

Country Link
US (2) US10857311B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019267308A1 (en) * 2018-05-08 2021-01-07 Omega Life Science Ltd. Nebulizers, nebulizer cartridges and uses thereof
CN108873055B (en) * 2018-07-16 2020-11-10 中国原子能科学研究院 Instillation method of radioactive aerosol filter membrane standard source

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2284591A (en) * 1939-11-24 1942-05-26 Stanco Inc Nebulizer
US3046983A (en) * 1959-10-01 1962-07-31 Grubb Thomas Christman Variable dose inhaler
US3610480A (en) * 1969-07-31 1971-10-05 Geigy Chem Corp Aerosol dispensing apparatus
US3927806A (en) * 1972-09-07 1975-12-23 Philip Meshberg Applicator for attachment to a spray mist dispenser
US4114811A (en) * 1977-04-12 1978-09-19 Ciba-Geigy Corporation Spray dispenser with easily actuable mouthpiece
GB2074454A (en) * 1980-04-24 1981-11-04 Somova Spa Inhalation device with retractible mouthpiece
US4969455A (en) * 1988-11-29 1990-11-13 Somova S.P.A. Inhalator for aerosol containers
US5755221A (en) * 1990-09-12 1998-05-26 Bisgaard; Hans Aerosol inhaler with piston dump
US5833057A (en) * 1997-04-28 1998-11-10 Char; Aka Loka Apparatus for packaging and shipping biological fluid samples collected in vials
US6354516B1 (en) * 1999-11-02 2002-03-12 Aradigm Corporation Pore structures for reduced pressure aerosolization
US20020073991A1 (en) * 1998-01-22 2002-06-20 Igor Gonda Formulation and devices for monitoring the efficacy of the delivery of aerosols
US20060231090A1 (en) * 2005-04-13 2006-10-19 Russell King Inhalation apparatus
US20070175476A1 (en) * 2005-12-28 2007-08-02 Philip Morris Usa Inc. Aerosol powder delivery device
US20080216828A1 (en) * 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US20090192443A1 (en) * 2008-10-06 2009-07-30 Collins Jr James F Ophthalmic fluid delivery device and method of operation
US20120318259A1 (en) * 2010-01-12 2012-12-20 Omega Life Science Ltd. Method and apparatus for producing fine concentrated aerosol

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023063A (en) 1911-01-03 1912-04-09 Lowell C Bassford Window-screen.
US1132679A (en) 1914-10-14 1915-03-23 Thomas E Murray Method of neutralizing corrosive fumes in gases.
FR648541A (en) 1929-01-14 1928-12-11
US2276878A (en) 1940-08-22 1942-03-17 Stanco Inc Nebulizer
US2348420A (en) 1942-06-10 1944-05-09 William H Rose Liquid spraying device
US3583635A (en) 1969-02-24 1971-06-08 Jerome H Lemelson Spraying systems
US3570038A (en) 1969-10-22 1971-03-16 Vernon F Jones Bottle brush structure
US3762409A (en) 1970-11-03 1973-10-02 V Lester Nebulizer
US3771721A (en) 1972-09-06 1973-11-13 Respiratory Care Nebulizer
US3812854A (en) 1972-10-20 1974-05-28 A Michaels Ultrasonic nebulizer
GB8325047D0 (en) 1983-09-19 1983-10-19 Medica Aid Ltd Nebulizers
SE449440B (en) 1983-12-19 1987-05-04 Jr Mans Arborelius NEBULIZER FOR SUBMICRON PREPARATION, HOMOGEN AEROSOL
US4941618A (en) 1986-07-07 1990-07-17 Leeman Labs Inc. Nebulizer employing a fine mesh screen
US4743407A (en) 1986-11-21 1988-05-10 The United States Of America As Represented By The United States Department Of Energy Externally pressurized porous cylinder for multiple surface aerosol generation and method of generation
US4832012A (en) 1987-07-08 1989-05-23 Vortran Medical Technology, Inc. Intermittent signal actuated nebulizer
US4907581A (en) 1988-06-30 1990-03-13 Medi-Nuclear Corporation, Inc. Radioactive aerosol inhalation apparatus
US4947874A (en) 1988-09-08 1990-08-14 R. J. Reynolds Tobacco Company Smoking articles utilizing electrical energy
US5030390A (en) 1989-07-20 1991-07-09 University Of Delaware Process for cooling water in an inflated fabric cooling dome
GB8917775D0 (en) 1989-08-03 1989-09-20 Atomic Energy Authority Uk Aerosol inhaler
US5152456A (en) 1989-12-12 1992-10-06 Bespak, Plc Dispensing apparatus having a perforate outlet member and a vibrating device
GB9021433D0 (en) 1990-10-02 1990-11-14 Atomic Energy Authority Uk Power inhaler
US5277175A (en) 1991-07-12 1994-01-11 Riggs John H Continuous flow nebulizer apparatus and method, having means maintaining a constant-level reservoir
US5301664A (en) 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
US5379760A (en) 1992-10-26 1995-01-10 Ryder; Steven L. Position insensitive low resistance aspirator
GB2272389B (en) 1992-11-04 1996-07-24 Bespak Plc Dispensing apparatus
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
JP3493366B2 (en) 1993-06-14 2004-02-03 日本モンサント株式会社 Connection structure of cartridge type chemical liquid container used for chemical liquid sprayer
DE4227899A1 (en) 1993-09-24 1994-02-24 Pfeiffer Erich Gmbh & Co Kg Discharge mechanism for fluidic media with discharge head(s) - has distributor(s) with medium receiver(s) for distribution and stationary reception of at least one medium
US5431345A (en) 1993-11-12 1995-07-11 The Procter & Gamble Company Foam dispensing system for a foamable liquid
US5570682A (en) 1993-12-14 1996-11-05 Ethex International, Inc. Passive inspiratory nebulizer system
US5479920A (en) 1994-03-01 1996-01-02 Vortran Medical Technology, Inc. Breath actuated medicinal aerosol delivery apparatus
US5810755A (en) 1994-10-17 1998-09-22 Leveen; Harry H. Medicated wound dressing
US5535989A (en) 1994-12-02 1996-07-16 Sen; Dipak K. Liquid film producing process and apparatus for fluid-liquid contacting
US5603314A (en) 1995-03-22 1997-02-18 Bono; Michael Aerosol filtration device and inhalation apparatus containing same
US6205999B1 (en) 1995-04-05 2001-03-27 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US5545456A (en) 1995-04-20 1996-08-13 Suida; Teresa Wash-cloth that cleans and massages
KR0144599B1 (en) 1995-07-01 1998-07-15 윤덕용 Liquid-drop generator and device for preparing fine-partides
US5823179A (en) 1996-02-13 1998-10-20 1263152 Ontario Inc. Nebulizer apparatus and method
WO1997048293A1 (en) 1996-06-17 1997-12-24 Japan Tobacco Inc. Flavor producing article
US5685291A (en) 1996-11-15 1997-11-11 Marsh; Jean Ann Nebulizer adapter system for premature babies
DE19720701A1 (en) 1997-05-16 1998-11-19 Gsf Forschungszentrum Umwelt Device for applying a medicament aerosol via the lungs
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
JPH11316031A (en) 1998-05-06 1999-11-16 Yasumasa Akazawa Air processing device
US6070575A (en) 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure
US6315272B1 (en) 1999-01-06 2001-11-13 Emerson Electric Co. Humidifier with stacked reservoir
US6196218B1 (en) 1999-02-24 2001-03-06 Ponwell Enterprises Ltd Piezo inhaler
AU3158600A (en) 1999-03-06 2000-09-28 Glaxo Group Limited Medicament delivery system
US6467477B1 (en) 1999-03-26 2002-10-22 Respironics, Inc. Breath-based control of a therapeutic treatment
IL129208A0 (en) 1999-03-28 2000-02-17 Liposol Ltd A method and apparatus for nebulizing a liquid particulary useful for the aerosol delivery of biopharmaceuticals
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
SE9902627D0 (en) 1999-07-08 1999-07-08 Siemens Elema Ab Medical nebulizer
US6530370B1 (en) 1999-09-16 2003-03-11 Instrumentation Corp. Nebulizer apparatus
US8820316B2 (en) 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
JP4777574B2 (en) 2000-02-11 2011-09-21 レスピロニクス・レスピラトリー・ドラッグ・デリバリー・(ユーケー)・リミテッド Drug administration device
US6443151B1 (en) 2000-03-08 2002-09-03 Aradigm Corporation Fluid velocity-sensitive trigger mechanism
US20050066968A1 (en) 2000-08-01 2005-03-31 Shofner Frederick M. Generation, delivery, measurement and control of aerosol boli for diagnostics and treatments of the respiratory/pulmonary tract of a patient
US6527257B1 (en) 2000-09-05 2003-03-04 Rps Products, Inc. Decorative humidifier and fountain combination
US7077130B2 (en) 2000-12-22 2006-07-18 Chrysalis Technologies Incorporated Disposable inhaler system
US6799572B2 (en) 2000-12-22 2004-10-05 Chrysalis Technologies Incorporated Disposable aerosol generator system and methods for administering the aerosol
ATE380578T1 (en) 2001-01-18 2007-12-15 Ultrasonic Dryer Ltd METHOD AND DEVICE FOR GENERATING DROPS
USD471626S1 (en) 2001-06-14 2003-03-11 Omron Corporation Nebulizer
US6729327B2 (en) 2001-12-17 2004-05-04 Joseph L. McFarland, Jr. Portable, handheld, pneumatic driven medicinal nebulizer
US20030205226A1 (en) 2002-05-02 2003-11-06 Pre Holding, Inc. Aerosol medication inhalation system
US20040045546A1 (en) 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
DE10243371B4 (en) 2002-09-18 2006-06-14 Pari GmbH Spezialisten für effektive Inhalation Aeorosoltherapiegerät
AU2002952683A0 (en) 2002-11-15 2002-11-28 Commonwealth Scientific And Industrial Research Organisation Apparatus for delivering dry aerosols to the respiratory tract
GB2395437C (en) 2002-11-20 2010-10-20 Profile Respiratory Systems Ltd Improved inhalation method and apparatus
GB2396825B (en) 2002-11-20 2004-12-08 Profile Respiratory Systems Lt Improved inhalation method and apparatus
US20040123863A1 (en) 2002-12-27 2004-07-01 Yi-Hua Wang Method of controlling oxygen inhaling through involuntary action of human and product thereof
GB0319119D0 (en) 2003-08-14 2003-09-17 Optinose As Delivery devices
WO2005102428A1 (en) 2004-04-23 2005-11-03 The Governors Of The University Of Alberta Enhanced drug delivery for inhaled aerosols
WO2006026026A2 (en) 2004-07-30 2006-03-09 Acrymed, Inc. Antimicrobial silver compositions
DE102005033398A1 (en) 2004-11-10 2006-05-11 Alfred Von Schuckmann Inhale device
US7900627B2 (en) 2005-01-18 2011-03-08 Respironics, Inc. Trans-fill method and system
US7634998B1 (en) 2005-07-15 2009-12-22 Fenley Robert C HME shuttle system
WO2008048234A2 (en) 2005-08-26 2008-04-24 North Carolina State University Inhaler system for targeted maximum drug-aerosol delivery
US20080082139A1 (en) 2006-10-02 2008-04-03 Mike John Means Inhalation therapy using audiovisual stimuli
US20080283049A1 (en) 2007-02-27 2008-11-20 Derek D Mahoney High efficiency nebulizer
US8371299B2 (en) 2007-04-19 2013-02-12 Respironics Respiratory Drug Delivery Ventilator aerosol delivery
US8261738B2 (en) 2007-07-24 2012-09-11 Respironics Respiratory Drug Delivery (Uk) Ltd. Apparatus and method for maintaining consistency for aerosol drug delivery treatments
WO2011021117A1 (en) 2009-08-15 2011-02-24 Koninklijke Philips Electronics, N.V. System and method for enabling therapeutic delivery of aerosolized medicament to a plurality of subjects to be monitored
US8925549B2 (en) 2008-08-11 2015-01-06 Surge Ingenuity Corporation Flow control adapter for performing spirometry and pulmonary function testing
US8695587B2 (en) 2008-09-26 2014-04-15 Incube Labs, Llc Controlled inhaler for distributing inhalant according to inhalation velocity
US20100092746A1 (en) 2008-10-14 2010-04-15 Jean-Marie Coant Nonwoven material containing benefiting particles and method of making
EP2376156B1 (en) 2008-12-11 2014-01-08 Koninklijke Philips N.V. System and method for monitoring a metered dose inhaler
US20100192321A1 (en) 2009-01-30 2010-08-05 3M Innovative Properties Company Hair and lint cleaning tool
JP2010207297A (en) 2009-03-09 2010-09-24 Canon Inc Liquid discharge device and method therefor
US9060715B2 (en) 2009-07-22 2015-06-23 Koninklijke Philips N.V. Nebulizer
JP5731521B2 (en) 2009-11-04 2015-06-10 コーニンクレッカ フィリップス エヌ ヴェ Pharmaceutical supply device including a drug metering system
CN102695535B (en) 2010-01-07 2016-03-30 皇家飞利浦电子股份有限公司 Comprise the respiratory medications conveyer device of feedback and compliant device
EP2523709B1 (en) 2010-01-11 2016-06-15 Koninklijke Philips N.V. Magnetic coupling for aerosol generating apparatus
AU2010340769B2 (en) * 2010-01-11 2015-02-12 Koninklijke Philips Electronics N.V. Magnetic coupling for aerosol generating apparatus
DE102010009852A1 (en) 2010-03-02 2011-09-08 Kalle Gmbh Antimicrobial finished films, sponges and sponge cloths
US8491491B2 (en) 2010-03-02 2013-07-23 Data Sciences International, Inc. Respiration measurements and dosimetry control in inhalation testing systems
US8944052B2 (en) 2011-05-26 2015-02-03 Ivan Osorio Apparatus and methods for delivery of therapeutic agents to mucous or serous membrane
US20130032153A1 (en) 2011-08-04 2013-02-07 Neely Travis Ray Mask for an air delivery apparatus, system, and method
EP2744599B1 (en) 2011-09-19 2016-07-13 Koninklijke Philips N.V. Analysis and control of aerosol output
US9572944B2 (en) 2011-09-19 2017-02-21 Koninklijke Philips N.V. Nebulizer, a control unit for controlling the same, a nebulizing element and a method of operating a nebulizer
US20130220314A1 (en) 2012-02-29 2013-08-29 General Electric Company Medical vaporizer with porous vaporization element
RU2630590C2 (en) 2012-03-07 2017-09-11 Конинклейке Филипс Н.В. Device for application with nebuliser and method for nebuliser actuation
GB2504075A (en) 2012-07-16 2014-01-22 Nicoventures Holdings Ltd Electronic smoking device
GB2504076A (en) 2012-07-16 2014-01-22 Nicoventures Holdings Ltd Electronic smoking device
US8807131B1 (en) 2013-06-18 2014-08-19 Isonea Limited Compliance monitoring for asthma inhalers
US9877509B2 (en) 2014-03-31 2018-01-30 Westfield Limited (Ltd.) Micro-vaporizer heating element and method of vaporization
US10201186B2 (en) 2014-08-22 2019-02-12 Fontem Holdings 4 B.V. Method, system and device for controlling a heating element
GB201511361D0 (en) 2015-06-29 2015-08-12 Nicoventures Holdings Ltd Electronic vapour provision system
GB201511349D0 (en) 2015-06-29 2015-08-12 Nicoventures Holdings Ltd Electronic aerosol provision systems
GB201511359D0 (en) 2015-06-29 2015-08-12 Nicoventures Holdings Ltd Electronic vapour provision system
CN205040652U (en) 2015-08-11 2016-02-24 上海烟草集团有限责任公司 Aerosol inhalation device
US10328218B2 (en) * 2015-10-15 2019-06-25 Engineered Medical Systems, Inc. Respiratory medicament nebulizer system
US9993027B1 (en) 2016-12-06 2018-06-12 Funai Electric Co., Ltd. Heater element for a vaporization device

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2284591A (en) * 1939-11-24 1942-05-26 Stanco Inc Nebulizer
US3046983A (en) * 1959-10-01 1962-07-31 Grubb Thomas Christman Variable dose inhaler
US3610480A (en) * 1969-07-31 1971-10-05 Geigy Chem Corp Aerosol dispensing apparatus
US3927806A (en) * 1972-09-07 1975-12-23 Philip Meshberg Applicator for attachment to a spray mist dispenser
US4114811A (en) * 1977-04-12 1978-09-19 Ciba-Geigy Corporation Spray dispenser with easily actuable mouthpiece
GB2074454A (en) * 1980-04-24 1981-11-04 Somova Spa Inhalation device with retractible mouthpiece
US4969455A (en) * 1988-11-29 1990-11-13 Somova S.P.A. Inhalator for aerosol containers
US5755221A (en) * 1990-09-12 1998-05-26 Bisgaard; Hans Aerosol inhaler with piston dump
US5833057A (en) * 1997-04-28 1998-11-10 Char; Aka Loka Apparatus for packaging and shipping biological fluid samples collected in vials
US20020073991A1 (en) * 1998-01-22 2002-06-20 Igor Gonda Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6354516B1 (en) * 1999-11-02 2002-03-12 Aradigm Corporation Pore structures for reduced pressure aerosolization
US20060231090A1 (en) * 2005-04-13 2006-10-19 Russell King Inhalation apparatus
US20070175476A1 (en) * 2005-12-28 2007-08-02 Philip Morris Usa Inc. Aerosol powder delivery device
US20080216828A1 (en) * 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US20090192443A1 (en) * 2008-10-06 2009-07-30 Collins Jr James F Ophthalmic fluid delivery device and method of operation
US20120318259A1 (en) * 2010-01-12 2012-12-20 Omega Life Science Ltd. Method and apparatus for producing fine concentrated aerosol

Also Published As

Publication number Publication date
US10857311B2 (en) 2020-12-08
US20170189628A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
US9707206B2 (en) Mast cell stabilizers treatment for systemic disorders
Newman Aerosol deposition considerations in inhalation therapy
ES2792682T3 (en) Methods for the treatment of lung diseases with mast cell stabilizers
AU2017228051B2 (en) Nicotine formulation and aerosols
JP2006527046A (en) Powder aerosol feeder
US20210046258A1 (en) Method and apparatus for producing fine concentrated aerosol
US20230355583A1 (en) Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
Ariyananda et al. Aerosol delivery systems for bronchial asthma
WO2009105445A1 (en) Effective delivery of nanoparticles and micrometer-sized pharmaceutical aerosols to the lung through enhanced condensational growth
Kaur et al. Advanced aerosol delivery devices for potential cure of acute and chronic diseases
Kaur Pulmonary drug delivery system: newer patents
MX2013004030A (en) Method for treating cystic fibrosis with inhaled denufosol.
CN114652704A (en) Tryprostinil soft mist inhalant
HUT76861A (en) An aerosol product and method for producing those
JP2009531070A (en) Powder aerosol feeder
WO2017157265A1 (en) Spray, spraying device and spray module
Salvi et al. A practical guide on the use of inhaler devices for asthma and COPD
Alberts et al. Effect of Aerosol Devices and Administration Techniques on Drug Delivery in a Simulated Spontaneously Breathing Pediatric Tracheostomy Model
Tattersfield et al. Methods of Drug Administration
Singhal et al. Aerosol Drug Delivery
Rahul et al. RECENT ADVANCES IN PULMONARY DRUG DELIVERY SYSTEM.
Op’t Holt Evolution of the inhalation of vapors and aerosols in the care of asthma and other respiratory diseases
Mittal et al. World Journal of Pharmaceutical Sciences
MXPA06006284A (en) Portable gas operating inhaler

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

AS Assignment

Owner name: OMEGA LIFE SCIENCE LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SADYKHOV, AKPER;REEL/FRAME:054761/0273

Effective date: 20120703

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION